Loading patent…
AssigneeCavion, Inc.
InventorsMargaret S. LEE, Spyridon PAPAPETROPOULOUS, Michelle S. HIGGIN, Muralikrishna DUVVURI, Bruce N. REHLAENDER, Evan NEWBOLD
Estimating the term…
This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.
-50. (canceled)
An oral dosage form comprising a Cav3 antagonist, wherein the Cav3 antagonist is CX-8998
A method of treating a human having a movement disorder, said method comprising administering once daily to said human an oral dosage form, wherein said oral dosage form comprises a Cav3 antagonist, wherein the Cav3 antagonist is CX-8998
Dependencies are inferred from the claim text.